Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

J Clin OncolAug 11, 2026 (epub)
Clinical ResearchOncology (Medical)

Guang-Liang Chen, Yanjing Guo, Xin Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II trial evaluated trastuzumab rezetecan in patients with unresectable advanced salivary gland carcinoma (SGC), stratified by HER2 expression levels. Among 46 patients, the confirmed objective response rate was 91.7% in the HER2-high cohort and 45.5% in the HER2-low cohort. Median progression-free survival was 12.7 months in the HER2-low group, with no treatment-related deaths reported.

Key findings

  • Confirmed objective response rate was 91.7% in the HER2-high cohort.
  • Confirmed objective response rate was 45.5% in the HER2-low cohort.
  • Median progression-free survival was 12.7 months in the HER2-low cohort.
  • Grade 3 or higher treatment-related adverse events occurred in 41.3% of patients.

Why it matters

The study highlights the potential of trastuzumab rezetecan as a treatment option for advanced salivary gland carcinoma, particularly in patients with high HER2 expression, addressing a significant gap in therapeutic options for this rare cancer.

Source

PubMed · PMID 42579830

Published in J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.